RESUMO
OBJECTIVE To compare the efficacy and safety of bimatoprost and latanoprost in the treatment of glaucoma， and to provide evidence-based reference for clinical rational drug use. METHODS PubMed， Embase， the Cochrane Library， China Biology Medicine disc， CNKI， Wanfang Data， and VIP databases were searched by computer to collect the randomized controlled trials （RCTs） about bimatoprost （trial group） versus latanoprost （control group） in the treatment of glaucoma from the inception to March 2022. After screening the literature and extracting the data， the qualities of the included literature were evaluated using the bias risk assessment tool recommended by the Cochrane system evaluator manual 5.1.0. Meta-analysis， sensitivity analysis and publication bias analysis were performed by using RevMan 5.4 and Stata 12 software. RESULTS A total of 2 181 patients were enrolled in 19 RCTs. Meta-analysis results showed that， the end point intraocular pressure reduction （IOPR） [MD＝0.89， 95%CI （0.53，1.25）， P＜0.000 01] of patients in trial group was significantly lower than control group， while the incidence of conjunctival congestion [RR＝1.89， 95%CI （1.59， 2.24）， P＜0.000 01] and eyelash growth [RR＝3.17， 95%CI （1.97，5.08）， P＜0.000 01] were significantly higher than control group. There was no significant difference in the incidence of eye irritation/foreign body sensation， pruritus， dry eye， eye inflammation， eye pain， visual impairment or iris/skin pigmentation between 2 groups （P＞0.05）. Results of subgroup analysis based on different medication time points showed that， the IOPR of patients in the trial group after 1， 3 and 6 months of treatment was significantly lower than control group （P＜0.05）. Results of sensitivity analysis showed that the result of this study was robust. The publication bias analysis showed that there was little possibility of publication bias in this study. CONCLUSIONS Compared with latanoprost， bimatoprost has more advantages in improving intraocular pressure， but the risk of conjunctival congestion and eyelash growth is higher than latanoprost.
RESUMO
Objective To understand the drug resistance and changes of Pseudomonas aeruginosa in Tianjin Medical University Eye Hospita and to explore the relationship between the drug resistance and the dosage of antimicrobial agents, so as to provide the basis for clinical rational drug use.MethodsUsage of antibiotics in our hospital during 2012 to 2016 were analyzed retrospectively, and the drug resistance of pseudomonas aeruginosa were calculated respectively.SPSS 22.0 software was used to analyze the drug resistance and the frequency of use of antimicrobial agents (DDDs).ResultsResistance rate of pseudomonas aeruginosa to aztreonam, ceftazidime and meropenem were decreased gradually.Resistance rate of pseudomonas aeruginosa to gentamicin increased gradually.The resistance of pseudomonas aeruginosa to piperacillin, imipenem, cefepime, evil ciprofloxacin, piperacillin/tazobactam tazobactam and cefempidone/sulbactam is in a state of fluctuation.Piperacillin DDDs were significantly negatively correlated with gentamicin resistance.There was a significant positive correlation between imipenem DDDs and gentamicin resistance and there was a significant negative correlation between imipenem DDDs and drug resistance rates of piperacillin, imipenem, ceftazidime, meropenem, levofloxacin and cefoperazone/sulbactam.There was a significant positive correlation between aztreonam DDDs and ceftazidime, meropenem, ciprofloxacin and cefoperazone/sulbactam, There was a significant negative correlation between cephalosporin DDDs and gentamicin resistance rates.There was a significant positive correlation between the DDDs of piperacillin/tazobactam and the resistance rate of piperacillin/tazobactam;the resistance rates of cefoperazone/sulbactam DDDs to aztreonam and meropenem were Significant negative correlation.ConclusionDrug resistance of pseudomonas aeruginosa and the dosage of clinical antibacterial drug is closely related, suggesting that clinicians should use antibiotics for clinical rationally, in order to reduce the number of drug resistance of pseudomonas aeruginosa.